Replies to post #330285 on ORIONS Money Stocks

[rayank]

SNTA: "I liked this stock at $5.00, and find it offers a very compelling risk-reward profile at $2.80. I remain bullish.

I like this report. It's pretty strong. Despite starting new trials and changes in management, expenses are down nicely. Having cash to last into Q4 2015 exceeded my expectations. 2015 will see a lot of important data points and will be a make or break year for the company. I still feel shares are a bargain here. Perhaps the best thing to come out of this report was hearing the CEO speak about her plans. She stated":

"I have been working closely with the Board and management team to develop a strategy for…partnerships to realize the tremendous value-potential in ganetespib, our HDC platform and other pipeline assets. Thanks to the high level of investigator interest in studying ganetespib, we continue to support investigator sponsored clinical trials in a broad range of indications. Our strategy, which we look forward to outlining in the months ahead, will be designed to support our goal of becoming a leading pharmaceutical company."

http://seekingalpha.com/article/2655065-update-synta-pharmaceuticals-reports-q3-earnings-where-i-went-wrong?uprof=51

[trade2much]

SNTA <Annotated Chart> Entered @ 3 and seems to have a VG good outlook
(see chart short term) JMHO Longer term PH3 12/31/15 and 6/30/16 interim and final for Galaxy trial ph3